Euroopan unioni - suomi - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfooma, mantle-cell - antineoplastiset aineet - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Suomi - suomi - Fimea (Suomen lääkevirasto)

nycomed austria gmbh - demecarii bromidum - silmätipat - 2.5 mg/ml - demekaari

Suomi - suomi - Fimea (Suomen lääkevirasto)

nycomed austria gmbh - demecarii bromidum - silmätipat - 5 mg/ml - demekaari

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion corporation - suxamethonium chloride dihydrate - injektio-/infuusioneste, liuos - 50 mg/ml - suksametoni

Suomi - suomi - Fimea (Suomen lääkevirasto)

ethypharm - suxamethonium chloride - injektio-/infuusioneste, liuos - 50 mg/ml - suksametoni